Short answer
Maze Therapeutics, Inc. (MAZE) filed an 8-K current report with the SEC on April 22, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). $144.7M net proceeds from 5.54M shares and 850,000 pre-funded warrants priced at $23.50 per share.
Maze Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- $144.7M net proceeds from 5.54M shares and 850,000 pre-funded warrants priced at $23.50 per share
- Capital raise creates meaningful equity dilution while extending projected operating runway into 2029
- Proceeds primarily fund MZE829 for AMKD and MZE782 for PKU and CKD development
- Pre-funded warrants exercisable immediately at $0.001 per share, subject to 4.99% or 9.99% ownership limits
- Offering signals continued reliance on equity financing to advance clinical candidates and support general corporate needs
Item EX-99.1 · Exhibit EX-99.1
- $150 million gross equity offering: 5,540,000 common shares at $23.50 plus pre-funded warrants for 850,000 shares
- Potential dilution of up to 6,390,000 shares, with warrants exercisable at $0.001 per share
- Proceeds funding MZE829 and MZE782 development, extending projected operations into 2029 with existing liquidity
- Offering priced through participation from new and existing healthcare-focused investors, including Farallon and T. Rowe Price
- Expected closing April 23, 2026, subject to customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Maze Therapeutics, Inc. 8-K filings
Get the next MAZE 8-K as it lands
Follow MAZE for push alerts, or ask the research agent what this filing means.